Screener
Aura Biosciences, Inc. AURA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of stock options | 56 | — |
| Proceeds from exercise of common stock warrants | 123 | — |
| Proceeds from ESPP purchases | 121 | 96 |
| Net cash provided by financing activities | 300 | 96 |
| Net increase in cash, cash equivalents and restricted cash | 25,305 | 6,554 |
| Effect of exchange rate changes on cash and cash equivalents | (27) | (21) |
| Cash, cash equivalents and restricted cash at beginning of period | 60,283 | 32,461 |
| Cash, cash equivalents and restricted cash at end of period | $85,561 | $38,994 |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s financing cash flow?
- Aura Biosciences, Inc. (AURA) reported financing cash flow of $300K in Q1 2026.
- How has Aura Biosciences, Inc.'s financing cash flow changed year-over-year?
- Aura Biosciences, Inc.'s financing cash flow increased by 212.5% year-over-year, from $96K to $300K.
- What is the long-term trend for Aura Biosciences, Inc.'s financing cash flow?
- Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s financing cash flow has grown at a -6.9% compound annual growth rate (CAGR), from $95.63M to $77.16M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Aura Biosciences, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude